

# DEPARTMENT OF THE AIR FORCE 59TH MEDICAL WING (AETC) JOINT BASE SAN ANTONIO - LACKLAND TEXAS



26 APR 2017

MEMORANDUM FOR SGVT

ATTN: LT COL JASON A. KELLY

FROM: 59 MDW/SGVU

SUBJECT: Professional Presentation Approval

- 1. Your paper, entitled <u>Case Report: Improved Homonymous Hemianopia with Hyperbaric Oxygen Therapy</u> presented at/published to <u>Undersea and Hyperbaric Medicine (Journal/Abstract)</u>; <u>Undersea and Hyperbaric Medical Society Annual Scientific Meeting, Naples FL, 29 June 2 July 2017</u> in accordance with MDWI 41-108, has been approved and assigned local file #<u>17182</u>.
- 2. Pertinent biographic information (name of author(s) title, etc.) has been entered into our computer file. Please advise us (by phone or mail) that your presentation was given. At that time, we will need the date (month, day and year) along with the location of your presentation. It is important to update this information so that we can provide quality support for you, your department, and the Medical Center commander. This information is used to document the scholarly activities of our professional staff and students, which is an essential component of Wilford Hall Ambulatory Surgical Center (WHASC) internship and residency programs.
- 3. Please know that if you are a Graduate Health Sciences Education student and your department has told you they cannot fund your publication, the 59th Clinical Research Division may pay for your basic journal publishing charges (to include costs for tables and black and white photos). We cannot pay for reprints. If you are a 59 MDW staff member, we can forward your request for funds to the designated Wing POC at the Chief Scientist's Office, Ms. Alice Houy, office phone: 210-292-8029; email address: alice.houy.civ@mail.mil.
- 4. Congratulations, and thank you for your efforts and time. Your contributions are vital to the medical mission. We look forward to assisting you in your future publication/presentation efforts.

LINDA STEEL-GOODWIN, Col, USAF, BSC Director, Clinical Investigations & Research Support

hinda Steel-Groodwin

## PROCESSING OF PROFESSIONAL MEDICAL RESEARCH/TECHNICAL PUBLICATIONS/PRESENTATIONS

#### **INSTRUCTIONS**

### USE ONLY THE MOST CURRENT 69 MDW FORM 3089 LOCATED ON AF E-PUBLISHING

- 1. The author must complete page two of this form:
  - a. In Section 2, add the funding source for your study [ e.g., 59 MDW CRO Graduate Health Sciences Education (GHSE) (SGS O&M); SGS R&D;
     Tri-Service Nursing Research Program (TSNRP); Defense Medical Research & Development Program (DMRDP); NIH; Congressionally Directed Medical Research Program (CDMRP); Grants; etc.]
  - in Section 2, there may be funding available for journal costs, if your department is not paying for figures, tables or photographs for your publication.
     Please state "YES" or "NO" in Section 2 of the form, if you need publication funding support.
- 2. Print your name, rank/grade, sign and date the form in the author's signature block or use an electronic signature.
- Attach a copy of the 59 MDW IRB or IACUC approval letter for the research related study. If this is a technical publication/presentation, state the type (e.g. case report, QA/QI study, program evaluation study, informational report/briefing, etc.) in the "Protocol Title" box.
- 4. Attach a copy of your abstract, paper, poster and other supporting documentation.
- Save and forward, via email, the processing form and all supporting documentation to your unit commander, program director or immediate supervisor for review/approval.
- 6. On page 2, have either your unit commander, program director or immediate supervisor:
  - a. Print their name, rank/grade, title; sign and date the form in the approving authority's signature block or use an electronic signature.
- 7. Submit your completed form and all supporting documentation to the CRD for processing (59crdpubspres@us.at.mii). This should be accomplished no later than 30 days before final clearance is required to publish/present your materials. If you have any questions or concerns, please contact the 59 CRD/Publications and Presentations Section at 292-7141 for assistance.
- The 59 CRD/Publications and Presentations Section will route the request form to clinical investigations, 502 (SG/UAC (Ethics Review) and Public Affairs
  (59 MDW/PA) for review and then forward you a final letter of approval or disapproval.
- Once your manuscript, poster or presentation has been approved for a one-time public release, you may proceed with your publication or presentation submission activities, as stated on this form. Note: For each new release of medical research or technical information as a publication/presentation, a new 59 MDW Form 3039 must be submitted for review and approval.
- 10. If your manuscript is accepted for scientific publication, please contact the 59 CRD/Publications and Presentations Section at 292-7141. This information is reported to the 59 MDW/CC. All medical research or technical information publications/presentations must be reported to the Defense Technical Information Center (DITC). See 59 MDWI 41-108, Presentation and Publication of Medical and Technical Papers, for additional information.
- 11. The Joint Ethics Regulation (JER) DoD 5500.07-R, Standards of Conduct, provides standards of ethical conduct for all DoD personnel and their interactions with other non-DoD entities, organizations, societies, conferences, etc. Part of the Form 3039 review and approval process includes a legal ethics review to address any potential conflicts related to DoD personnel participating in non-DoD sponsored conferences, professional meetings, publication/presentation disclosures to domestic and foreign audiences, DoD personnel accepting non-DoD contributions, awards, honoraria, gifts, etc. The specific circumstances for your presentation will determine whether a legal review is necessary. If you (as the author) or your supervisor oheok "NO" in blook 17 of the Form 3039, your recearch or technical documents will not be forwarded to the 602 ISGAJAC legal office for an ethios review. To assist you in making this decision about whether to request a legal review, the following examples are provided as a guideline:

For presentations before professional societies and like organizations, the 59 MDW Public Attains Office (PAO) will provide the needed review to ensure proper disclaimers are included and the subject matter of the presentation does not create any cause for DoD concern.

If the sponsor of a conference or meeting is a DoD entity, an ethics review of your presentation is not required, since the DoD entity is responsible to obtain all approvals for the event.

If the sponsor of a conference or meeting is a non-DoD commercial entity or an entity seeking to do business with the government, then your presentation should have an ethics review.

If your travel is being paid for (in whole or in part) by a non-Federal entity (someone other than the government), a legal ethics review is needed. These requests for legal review should come through the 59 MDW Gifts and Grants Office to 502 ISG/UAC.

If you are receiving an honorarium or payment for speaking, a legal ethics review is required.

If you (as the author) or your supervisor check "YES" in block 17 of the Form 3039, your research or technical documents will be forwarded simultaneously to the 502 ISGNAC legal office and PAO for review to help reduce turn-around time. If you have any questions regarding legal reviews, please contact the legal office at (210) 671-5795/3365, DSN 473.

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement:

"The views expressed are those of the [author(s)] [presenter(s)] and do not reflect the official views or policy of the Department of Defense or its Components"

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving humans:

"The voluntary, fully informed consent of the subjects used in this research was obtained as required by 32 CFR 219 and DODI 3216.02\_AFI 40-402."

NOTE: All abstracts, papers, posters, etc., should contain the following disclaimer statement for research involving animals, as required by AFMAN 40-401\_IP:

"The experiments reported herein were conducted according to the principles set forth in the National institute of Health Publication No. 80-23, Guide for the Care and Use of Laboratory Animals and the Animal Welfare Act of 1966, as amended."

PROCESSING O	F PROFESS	IONAL MEDICAL	RESEAR	CH/TECHNICAL	PUBLICATIO	NS/PRES	SENTATIONS	
TO: CUNICAL RESEARCH	2. FROM: (Aut		ie, Office Sy			TUDENT: 4	, PROTOCOL NUMBER:	
5. PROTOCOL TITLE: (NOTE must I		elease of medical resea review and approval.)	irch ar techn	ical information as a	publication/prese	ntation, a ne	ew 59 MDW Form 3039	
6. TITLE OF MATERIAL TO B								
Case Report: Improved Ho	monymous Her	manopia with Hypert	baric Oxyg	en Inerapy				
7. FUNDING RECEIVED FOR	THIS STUDY? [	YES NO FUN	NDING SOU	RCE:				
8. DO YOU NEED FUNDING	SUPPORT FOR F	PUBLICATION PURPO	SES: Y	ES NO		La x		
9. IS THIS MATERIAL CLASS		thread .						
10. IS THIS MATERIAL SUBJI AND DEVELOPMENT AGREE YES NO NOTE: If the	MENT (CRADA),	MATERIAL TRANSFEI	R AGREEME	ENT (MTA), INTELL	ECTUAL PROPE	RTY RIGHT	8 AGREEMENT ETC.?	
11. MATERIAL IS FOR: X				EST ATTACHES	DV OF MATERIA	TORERI	DI IGUEN/DDECENTEN	
CHECK APPROPRIATE B  11a. PUBLICATION/JOU  Undersea and Hyperba	JRNAL (List inter			ESI. AIIAOHOL	PY OF MATERIA	LIOBEFO	BLISHEUPRESENTED.	
☑ 11b. PUBLISHED ABST Undersea and Hyperba		ded Journal.)						
☐ 11c. POSTER (To be de Undersea and Hyperba								
11d. PLATFORM PRESI	ENTATION (Ato	Ivilian institutions: name	of meeting,	state, and date of n	neting.)			
11e. OTHER (Describe:	name of meeting	, city, state, and date of	f meeting.)					
12. HAVE YOUR ATTACHED	RESEARCH/TEC	CHNICAL MATERIALS	BEEN PREV	IOUSLY APPROVE	TO BE PUBLIS	HED/PRES	ENTED?	
YES NO ASSIG	NED FILE#		DATE					
13. EXPECTED DATE WHEN NOTE: All publications/pr						ION TO DTI	С	
DATE								
April 30, 2017							Annual State of the Control of the C	
14. 59 MDW PRIMARY POINT Kelly, Jason A., jason a kel			e, M.I., email	)		15. DUTY PHONE/PAGER NUMBER 940-782-8983		
16. AUTHORSHIP AND CO-A	UTHOR(S) List I	in the order they will app	ear in the m	anuscript.				
LAST NAME, FIRST NAM a. Primary/Corresponding Auli		GRADE/RANK	SQU	SQUADRON/GROUP/OFFICE SYMBOL		INST	INSTITUTION (If not 59 MDW)	
Jason A. Kelly	ior	Lt Col	59 TRS		59 MI	59 MDW		
b. John B. Slade		Col (ret)	60 AMDS		60 MI	60 MDG		
c.								
d.								
e.	LAR							
17. IS A 502 ISG/JAC ETHICS	REVIEW REQU	WRED (JER DOD 5500)	07-R)?	YES X NO				
I CERTIFY ANY HUMAN OR A 219, AFMAN 40-401_JP, AND ACCURATE MANUSCRIPT FO	59 MDWI 41-108	. I HAVE READ THE FI	INAL VERSI	PROVED AND PER ON OF THE ATTAC	RFORMED IN STE CHED MATERIAL	AND CERTI	RDANCE WITH 32 CFR FY THAT IT IS AN	
18. AUTHOR'S PRINTED NAME, RANK, GRADE JASON A. KELLY, Lt Col			19.	19. AUTHOR'S SIGNATURE KELLY JASONA 1234294730 ESSESSIVE			20. DATE March 09, 2017	
21. APPROVING AUTHORITY'S PRINTED NAME, RANK, TITLE Michael F. Richards, Colonel, Hyperbaric Medicine Chief							23. DATE March 10, 2017	

PROCESSING OF PROFE	SSIONAL MEDICAL	RESEARCH/TECHNICAL PUBLICATIONS/PI	RESENTATIONS				
1st ENDORSEMENT (68 MDW/8GVU Use (							
TO: Clinical Research Division 59 MDW/CRD Contact 292-7141 for email instructions.	24. DATE RECEIVED April 07, 2017	25. ASSIGNED PROCESSING REQUEST FIL 17182	E NUMBER				
26. DATE REVIEWED		27. DATE FORWARDED TO 502 ISGUAC	27. DATE FORWARDED TO 502 ISGUAC				
April 25, 2017							
	ENDED OR NECESSARY	CHANGES: NO YES If yes, give date.	□ N/A				
29. COMMENTS X APPROVED DO  Single subject case study with appropria	SAPPROVED  ate disclaimers. Approv	ved					
30. PRINTED NAME, RANK/GRADE, TITLE	OF DEVICES	31. REVIEWER SIGNATURE	32. DATE				
Kevin Kupferer/GS13/Human Research		DELL KOPPERENCEVAN N. 1086867270 GENERALISMON	April 25, 2017				
2nd ENDORSEMENT (602 ISG/JAC Use Or	ily)						
33. DATE RECEIVED		34. DATE FORWARDED TO 59 MDWPA	34. DATE FORWARDED TO 59 MDWPA				
36. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	37. REVIEWER SIGNATURE	38. DATE				
			CI CANAL				
3rd ENDORSEMENT (69 MDW/PA Use Ont	n	La nue comune co comunicant					
39. DATE RECEIVED April 25, 2017		April 26, 2017	40. DATE FORWARDED TO 59 MDW/8GVU April 26, 2017				
41. COMMENTS X APPROVED (In con The presentation is approved and clears was provided.		policy review directives.)   DISAPPROVED  a presentation and abstract by Public Affairs, not as	a poster since no poster				
42. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	43. REVIEWER SIGNATURE	44. DATE				
Kevin Iimuma, SSgt/E-5, 59 MDW Publ		Spine specify the MANUFACTURE STATE I SHOOTHIS	April 26, 2017				
		THE THIN STATE SECRETARY STATES STATE	April 20, 2017				
4th ENDORSEMENT (68 MDW/8GVU Use (							
45. DATE RECEIVED	1	6. SENIOR AUTHOR NOTIFIED BY PHONE OF APPROV	LEFT MESSAGE				
47. COMMENTS APPROVED D	SAPPROVED						
48. PRINTED NAME, RANK/GRADE, TITLE	OF REVIEWER	49. REVIEWER SIGNATURE	50. DATE				

# Improved Homonymous Hemianopia with Hyperbaric Oxygen Therapy

### Introduction/Background

Homonymous visual-field defects result from insult to the retrochiasmal visual pathway, with 17% - 30% following acute stroke. Any recovery of a complete homonymous hemianopia typically occurs within the first 10 days after the ischemic event and improvement after 10-12 weeks is negligible. Only 38% - 48% of patients demonstrate any measurable improvement. No proven treatment exists for recovery of the impacted visual field.

This is a report of a 69 year old male hospitalized for 8 weeks with septic shock. He was discharged as a quadruple amputee due to necrotizing fasciitis and pressor-induced ischemia. On the day of admission the patient experienced cardiac arrest for approximately 15 minutes and was subsequently noted to have large areas of ischemic change in the occipital and parietal lobes bilaterally. Following discharge a complete left homonymous hemianopia was noted and approximately 5 months after initial insult hyperbaric oxygen treatments were initiated.

### **Materials and Methods**

The patient underwent 61 hyperbaric oxygen treatments in a multiplace chamber at 2.0 ATA for 90 minutes each. Visual field testing was performed by Humphrey Visual Field analysis. Baseline testing was performed, then after treatments 13, 31, 46, and 58 and again 6 months after treatment.

### Results

No significant improvement in the visual fields was noted at 13 treatments, but approximately 50% improvement was demonstrated in the right eye after 30 treatments with less improvement in the left. Continued improvement was noted after 46 treatments and plateau by 58 treatments.

### Summary/Conclusions

This case demonstrates significant objective improvement of a fixed neurologic deficit following an ischemic brain injury. Various hypotheses exist regarding the recovery of neurologic deficits to include collateral flow mechanisms, the zone of penumbra effect and reactivation of reversibly damaged nerve tissue. This case reveals partial recovery of a neurologic deficit through the use of hyperbaric oxygen, more than 5 months after the original insult.

The views expressed are those of the author and do not reflect the official views or policy of the Department of Defense or its Components.